The Advanced Model 3900 Multi-Sample Osmometer
Navigation Links
The Advanced Model 3900 Multi-Sample Osmometer
| Products | The Advanced Model 3900 Multi-Sample Osmometer |
| Company | Advanced Instruments, Inc. |
| Item | The Advanced Model 3900 Multi-Sample Osmometer |
| Features |
|
| Description | The Advanced Model 3900 Multi-Sample Osmometer is designed to automate testing for laboratories processing moderate to high volumes of samples. By using the industry-preferred method of freezing-point technology for an accurate determination of total concentration, combined with high, continuous throughput, the Advanced Instruments Model 3900 will provide your laboratory optimal efficiency - easily accurately, and reliably. |
| Info | Advanced Instruments, Inc. Customer Service: (800) 225-4034 Web site: http://www.aicompanies.com |
Related medicine products :
1. Immulite 2000 Advanced Immunoassay System
2. U-III Advanced Auto-Photomicrographic Film Camera
3. Hancock II Aortic Bioprostheses with CINCH Advanced Implant System
4. Mosaic Aortic Bioprosthesis with CINCH Advanced Implant System
5. Precision Xtra Advanced Diabetes Tester
6. IOPac Hand-Held Pachymeter (Standard and Advanced)
7. NAVIS - Nidek Advanced Vision Information System
8. FormFit Advanced Back Support
9. Advanced Tissue Arrayer
10. NUNC Advanced Piercable Polyethylene Sealing Tape, Clear, Non-Sterile
11. NUNC Advanced Polyolefin Sealing Tape, Clear, Non-Sterile
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery
The EVS is engineered to close arteriotomies with ease and precision. The ergonomic stapler with a simple trigger actvated mechanism, requires a single operator. A deliver sheath gently locks onto
...d of an absorbable collagen sponge and a specially...n absorbable self-tightening suture. The device se... primary components, the anchor and the collagen s...echanical means and is supplemented by the platele...
Spyglass angiography catheters, combined with St. Jude Medical hemostasis introducers and GuideRight guidewires, offer a safe and effective diagnostic angiography system.
Medicine Products:(Date:12/3/2008)...ic study found that patients with low-grade glioma...surgeries to successfully remove the entire tumor....ble, patients survived significantly longer when s...dy is available online as an advance publication i...rnals.org/cgi/content/abstract/15228517-2008-102v1...
(Date:12/3/2008)...ater Than Entire U.S. Economy , , DALLAS, D...vernment stopped the Medicare and Social Security ...xes and allowing no more accrual of benefits -- it...ave already earned these benefits, according to a ...is (NCPA). , , "The numbers are staggerin...
(Date:12/3/2008)...swire-FirstCall/ -- MAP,Pharmaceuticals, Inc. (Na...ill,participate in a panel discussion titled "Ada...ons" at the 2008 RBC Capital Markets Healthcare Co...0 am (ET) in New York City. , A live webcas... Investor,Relations section of MAP Pharmaceutical...
(Date:12/3/2008)...he Baccalaureate Student Population May Signal tha... , WASHINGTON, Dec. 3 /PRNewswire-USNewswire/ -...(AACN) today released preliminary survey data show...ursing programs increased by only 2.0 percent from...cutive year of enrollment growth, the annual incre...
Breaking Medicine News(10 mins):Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2Health News:Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 3Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 4Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 5[0] Mayo Clinic identifies best treatments for long-term survival in brain tumor patients[0] Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers[0] MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference[0] Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN
...t are fairly easy is gaining credibility in assist...fered heart failure. //Researchers at Washington U...gested that by simply counting the number of healt...e physician can use this barometer to assess the p...
... produced in the body have a significant role in t...f signaling protein called insulin-like growth fac...k of cancer. However, if its concentration is too ...rt stature, dementia, osteoporosis etc. New resea...
...ne remembers of an event mainly depends upon wheth...'package' the memory, according to researchers at ...ople recall only parts of an experience such as a ...ay vividly recall all of the details of a similar ...
...been permitted to perform womb transplantation on ...l transplant on a non-human primate, a rhesus monk...ork and Pittsburgh. The review board at New York ... to Dr Giuseppe Del Priore to carryout transplant ...
Other Medicine News:Health News:Severity of heart failure in elderly can be measured with a seven-point system 2Health News:Severity of heart failure in elderly can be measured with a seven-point system 3Health News:Effect Of Growth Factor Signals On Cancer Development 2Health News:Effect Of Growth Factor Signals On Cancer Development 3Health News:Memories Linked To Their Packaging In The Brain 2Health News:Human Uterine Transplant In Near Future 2(Date:12/2/2008)... -- Biopure Corporation,(Nasdaq: BPUR ) announc...er,(NMRC) has submitted to the Food and Drug Admi...ug (IND) application to conduct a clinical trial o...emoglobin glutamer - 250 (bovine)],for the pre-ho...he study is,entitled "Operation Restore Effective...
(Date:12/2/2008)... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceut...ies for the treatment of cancer, inflammation and ...ntered into an agreement expanding its Committed E...apital Limited, a private investment group. Under...tted to provide up to $75 million of capital durin...
(Date:12/1/2008)...announced that an oral,presentation of prelimina...,trial of TG101348 in myeloproliferative disease p...ociety of Hematology (ASH) Meeting. , , Det...tle: A Phase I Study of TG101348, an ...Selective Inhibitor, in Patients with, ...
(Date:12/1/2008)...y switch that, if turned off, causes lymphatic end...e their identity and become more like blood endoth...ewswire-USNewswire/ -- Scientists at St. Jude Chi...ertain differentiated cell type is so ready to cha...ression of a gene called Prox1 to dissuade it. ...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Individuals vary their immune response according to age sex and the costs 4817 1Individuals vary their immune response according to age sex and the costs 4817 2TSC honors Sen Charles Schumer 4814 1Beverage Industry Continues Cutting Calories in Schools Delivering on Its Commitment to Change Beverage Mix 26270 1Beverage Industry Continues Cutting Calories in Schools Delivering on Its Commitment to Change Beverage Mix 26270 2Beverage Industry Continues Cutting Calories in Schools Delivering on Its Commitment to Change Beverage Mix 26270 3Beverage Industry Continues Cutting Calories in Schools Delivering on Its Commitment to Change Beverage Mix 26270 4El Camino Hospital Selects ITelagen for Multimillion Dollar Electronic Medical Records 28EMR 29 Initiative 3B Program Will Offer More Than 100 Partic 26267 1El Camino Hospital Selects ITelagen for Multimillion Dollar Electronic Medical Records 28EMR 29 Initiative 3B Program Will Offer More Than 100 Partic 26267 2El Camino Hospital Selects ITelagen for Multimillion Dollar Electronic Medical Records 28EMR 29 Initiative 3B Program Will Offer More Than 100 Partic 26267 3[0] U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting[0] Micromet Expands Committed Equity Financing Facility to $75 Million[0] TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients[0] Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
...e for Second Pivotal Phase 3 Trial CL-05, CHICAGO,...Life,Sciences Holdings, Inc. , today announced the...rial CL-06, the first of two,pivotal Phase 3 clini...tiveness of cethromycin, a novel once-a-day antibi...monia (CAP). The Company,also provided an update t...
...007 -- Ablynx today announced positive,interim res...velopment programme, ALX-0081, an anti-thrombotic ...ss´ therapeutic,Nanobody® targeting von ... of thrombosis in patients with acute coronary,syn...s designed to assess,safety, tolerability and phar...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |